Biosion Inc, a China-based clinical-stage biotechnology company developing innovative antibody-based therapeutics, announced on Tuesday that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated Trial (IIT) assessing BSI-082, a highly differentiated, fully human anti-SIRP alpha monoclonal antibody.
This study is sponsored by and being conducted at the Mays Cancer Center, a National Cancer Institute (NCI)-designated Cancer Center and part of The University of Texas at San Antonio's Health Science Center.
BSI-082 is engineered to block the CD47-SIRP alpha 'don't eat me' signal, a critical checkpoint that tumour cells use to evade macrophage phagocytosis. Unlike other candidates in the class, BSI-082 was designed using Biosion's proprietary H3 Antibody Discovery Platform to overcome historical development challenges.
The Phase 1a/1b study is an open-label, dose-escalation and dose-expansion trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of BSI-082 in patients with locally advanced or metastatic solid tumours.
Phase 1a will establish the recommended dose for expansion (RDE) of BSI-082 as a monotherapy, and Phase 1b will evaluate BSI-082 in combination with trastuzumab deruxtecan (T-DXd) in patients with HER2-positive solid tumours.
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
US WorldMeds acquires Orbus Therapeutics
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult